Low-dose versus high-dose methylprednisolone for children with severe Mycoplasma pneumoniae pneumonia (MCMP): Study protocol for a randomized controlled trial

Baoping Xu, Xiaoxia Peng, Yao Yao, Ju Yin, Lanqin Chen, Jun Liu, Hao Wang, Liwei Gao, Adong Shen, Kunling Shen, Baoping Xu, Xiaoxia Peng, Yao Yao, Ju Yin, Lanqin Chen, Jun Liu, Hao Wang, Liwei Gao, Adong Shen, Kunling Shen

Abstract

Background: Severe Mycoplasma pneumoniae pneumonia (MPP) may develop with long-term pulmonary outcomes despite treatment with macrolides. Combined treatment with glucocorticoids can improve this outcome, though the optimal dosage is unknown. The aim of this study was to investigate the effects of low- and high-dose methylprednisolone in reducing the percentage of long-term pulmonary outcomes for children with severe MPP.

Methods: A randomized, single-blind, parallel-controlled, multicenter clinical trial, methylprednisolone for children with severe M. pneumoniae pneumonia (MCMP), is being conducted in China. Pediatric patients (≤18 years of age, expected number = 402) admitted to the hospital with a clinical diagnosis of severe MPP and fulfilling inclusion and exclusion criteria are randomized (ratio of 1:1) to either a low-dose (2 mg/kg/d) or high-dose (10 mg/kg/d) methylprednisolone treatment group for 3 days followed by tapering of methylprednisolone over 12 days and combined with azithromycin. The primary composite outcome will be incidence of atelectasis, bronchiectasis, or bronchiolitis obliterans at 6-months after treatment. Secondary outcomes include recovery time of patient temperature, proportion of pulmonary lesions absorbed, changes of mucosa identified by bronchoscopy, length of hospital stay, pulmonary function and number of participant(s) needing intensive care. Assessments will be made at baseline, post-treatment and at 1-month, 3-month and 6-month follow-ups.

Discussion: This is the first randomized clinical trial designed to evaluate the safety and efficacy of low- versus high-dose methylprednisolone for reducing long-term pulmonary outcomes in pediatric patients with severe MPP. The results of this study will provide scientific evidence to guide clinical practice for the treatment of severe MPP. Trial registration: This study is registered at ClinicalTrials.gov (NCT02303587).

Keywords: Children; Glucocorticoids; Severe Mycoplasma pneumoniae pneumonia.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2018 Chinese Medical Association. Pediatric Investigation published by John Wiley & Sons Australia, Ltd on behalf of Futang Research Center of Pediatric Development.

Figures

Figure 1
Figure 1
Study design flow diagram.

References

    1. Ma H, Sun L, Wu X, et al. The etiology of community‐acquired pneumonia in hospitalized children of single center in Beijing. Chin J Evid Based Pediatr. 2015;10:361‐365. (In Chinese).
    1. Jain S, Williams DJ, Arnold SR, et al. Community‐acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372:835‐845.
    1. Yu Z, Liu X, Jiang Z. Analysis of relevant factors of severe Mycoplasma pneumoniae pneumonia in acute phase in children. Chin J Appli Clin Pediatr. 2011;4:246‐249. (In Chinese).
    1. Jin J, Wang L, Zhang MZ. Clinical features and bronchoscopy treatment for 378 patients of Mycoplasma pneumoniae pneumonia in children. Chongqing Medicine. 2015;44:4815‐4817. (In Chinese).
    1. Wang L, Duan J. Clinical report on 68 cases of refractory Mycoplasma pneumoniae pneumonia (RMPP). Chinese Journal of Experimental and Clinical Virology. 2011;25:224‐226. (In Chinese).
    1. Eun BW, Kim NH, Choi EH, Lee HJ. Mycoplasma pneumoniae in Korean children: the epidemiology of pneumonia over an 18‐year period. J Infect. 2008;56:326‐331.
    1. Diaz MH, Benitez AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol. 2015;53:124‐130.
    1. Takiguchi Y, Shikama N, Aotsuka N, et al. Fulminant My c opl asma pne umoni ae pne um oni a. Int e rn Me d. 2001;40:345‐348.
    1. Youn YS, Lee SC, Rhim JW, et al. Early additional immune‐m odulators for Mycoplasma pneumoniae pneumonia in children: An observation study. Infect Chemother. 2014;46:239‐247.
    1. Bradley JS, Byington CL, Shah SS, et al. The management of community‐acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53:e25‐76.
    1. Uehara S, Sunakawa K, Eguchi H, et al. Japanese guidelines for the management of respiratory infectious diseases in children 2007 with focus on pneumonia. Pediatr Int. 2011;53:264‐276.
    1. Respiratory Branch of Chinese Pediatric Society of Editorial Board of Chinese Journal of Applied Clin . Expert consensus on diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2015). Chin J Appl Clin Pediatr. 2015;30:1304‐1308. (In Chinese)
    1. Luo Z, Luo J, Liu E, et al. Effects of prednisolone on refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2014;49:377‐380.
    1. Lee KY, Lee HS, Hong JH, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2006;41:263‐268.
    1. You SY, Jwa HJ, Yang EA, et al. Ef fects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in Children. Allergy Asthma Immunol Res. 2014;6:22‐26.
    1. Tamura A, Matsubara K, Tanaka T, et al. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect. 2008;57:223‐228.
    1. Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2012;55:42‐47.
    1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med. 2005;353:1711‐1723.
    1. Hu YM, Jiang ZF, editors. Zhu Futang's Practical Pediatrics (7th ed). 2002:1175‐1180.
    1. Subspecialty Group of Respiratory Diseases, The Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics . Guidelines of management of community acquired pneumonia in children (the revised edition of 2013). Chin J Pediatr. 2013;51:745‐752. (In Chinese)
    1. Chen L, Liu J, Zhao S, Yang Y, Wu J. Clinical features and treatment of refractory Mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children. Chin J Pediatr. 2014;52:172‐176. (In Chinese).
    1. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community‐acquired pneumonia requiring hospitalization. Lung. 2007;185:249‐255.
    1. Wan YD, Sun TW, Liu ZQ, et al. Efficacy and safety of corticosteroids for community‐acquired pneumonia: A systematic review and meta‐analysis. Chest. 2016;149:209‐219.
    1. Nagy B, Gaspar I, Papp A, et al. Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pediatr Pulmonol. 2013;48:168‐175.
    1. Lan Y, Yang D, Chen Z, et al. Effectiveness of methylprednisolone in treatment of children with refractory Mycoplasma pneumoniae pneumonia and its relationship with bronchoalveolar lavage cytokine levels. Chin J Pediatr. 2015;53:779‐783. (In Chinese).
    1. Steigbigel NH. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Curr Infect Dis Rep. 2003;5:363‐364.
    1. Hirao S, Wada H, Nakagaki K, et al. Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone. FEMS Immunol Med Micr obiol. 2011;62:182‐189.
    1. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high‐dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653‐658.
    1. Polverino E, Cilloniz C, Dambrava P, et al. Systemic corticosteroids for community‐acquired pneumonia: reasons for use and lack of benefit on outcome. Respirology. 2013;18:263‐271.
    1. Liu Y, Ye X, Zhang H, et al. Characterization of macrolide resistance in Mycoplasma pneum oniae isolated from children in Shanghai. China. Diagn Microbiol Infect Dis. 2010;67:355‐358.
    1. Feng X, Li Q, Sun L, et al. The clinical characteristics of macrolide‐resistant Mycoplasma pneumoniae pneumonia in Children: a case‐control study. Chin J Evid Based Pediatr. 2016;11:357‐360. (In Chinese).
    1. Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide‐resistant Mycoplasma pneumoniae . Antimicrob Agents Chemother. 2006;50:709‐712.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel